Shimura H, Hattori N, Kubo Si, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T.
Nat Genet 2000 Jul;25(3):302-5

Autosomal recessive juvenile parkinsonism: a key to understanding nigral degeneration in sporadic Parkinson's disease.
Hattori N, Shimura H, Kubo S, Kitada T, Wang M, Asakawa S, Minashima S, Shimizu N, Suzuki T, Tanaka K, Mizuno Y.
Neuropathology 2000 Sep;20 Suppl:S85-90

Asymmetric cortico-cortical inhibition in patients with progressive limb-kinetic apraxia.
Okuma Y, Urabe T, Mochizuki H, Miwa H, Shimo Y, Mori H, Mizuno Y.
Acta Neurol Scand 2000 Oct;102(4):244-8

Accumulation of 4-hydroxynonenal-modified proteins in hippocampal CA1 pyramidal neurons precedes delayed neuronal damage in the gerbil brain.
Urabe T, Yamasaki Y, Hattori N, Yoshikawa M, Uchida K, Mizuno Y.
Neuroscience 2000;100(2):241-50

A case of frontotemporal dementia with tau P301L mutation in the Far East.
Tanaka R, Kobayashi T, Motoi Y, Anno M, Mizuno Y, Mori H.
J Neurol 2000 Sep;247(9):705-7

Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification.
Yamamura Y, Hattori N, Matsumine H, Kuzuhara S, Mizuno Y.
Brain Dev 2000 Sep;22 Suppl 1:S87-91

Importance of familial Parkinson's disease and parkinsonism to the understanding of nigral degeneration in sporadic Parkinson's disease.
Hattori N, Shimura H, Kubo S, Wang M, Shimizu N, Tanaka K, Mizuno Y.
J Neural Transm Suppl 2000;(60):101-16

Inhibition of tyrosinase reduces cell viability in catecholaminergic neuronal cells.
Higashi Y, Asanuma M, Miyazaki I, Ogawa N.
J Neurochem 2000 Oct;75(4):1771-4

Delayed neuronal death in hippocampal CA1 pyramidal neurons after forebrain ischemia in hyperglycemic gerbils: amelioration by indomethacin.
Kondo F, Kondo Y, Makino H, Ogawa N.
Brain Res 2000 Jan 17;853(1):93-8

Antioxidants protect against dopamine-induced metallothionein-III (GIF) mRNA expression in mouse glial cell line (VR-2g).
Sogawa CA, Miyazaki I, Sogawa N, Asanuma M, Ogawa N, Furuta H.
Brain Res 2000 Jan 24;853(2):310-6

Protective effect of oren-gedoku-to against induction of neuronal death by transient cerebral ischemia in the C57BL/6 mouse.
Kondo Y, Kondo F, Asanuma M, Tanaka K, Ogawa N.
Neurochem Res 2000 Feb;25(2):205-9

Chronic cerebral hypoperfusion induces transient reversible monoaminergic changes in the rat brain.
Tanaka K, Wada N, Ogawa N.
Neurochem Res 2000 Feb;25(2):313-20

Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum.
Ogawa N, Tanaka K, Asanuma M.
Neurochem Res 2000 Jun;25(6):755-8

Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506.
Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T.
Neurosci Lett 2000 Aug 11;289(3):165-8

Direct interactions of methamphetamine with the nucleus.
Asanuma M, Hayashi T, Ordonez SV, Ogawa N, Cadet JL.
Brain Res Mol Brain Res 2000 Sep 15;80(2):237-43

Medullary monoamine levels during experimental tooth movement.
Yamashiro T, Kabuto H, Fukunaga T, Ogawa N, Takano-Yamamoto T.
Brain Res 2000 Sep 29;878(1-2):199-203

Expression of metallothionein-III mRNA and its regulation by levodopa in the basal ganglia of hemi-parkinsonian rats.
Miyazaki I, Sogawa CA, Asanuma M, Higashi Y, Tanaka KI, Nakanishi T, Ogawa N.
Neurosci Lett 2000 Oct 20;293(1):65-8

Immunophilin ligands prevent H2O2-induced apoptotic cell death by increasing glutathione levels in neuro 2A neuroblastoma cells.
Tanaka K, Fujita N, Asanuma M, Ogawa N.
Acta Med Okayama 2000 Dec;54(6):275-80

Immunosuppressive and non-immunosuppressive immunophilin ligands improve H(2)O(2)-induced cell damage by increasing

glutathione levels in NG108-15 cells.
Tanaka K, Fujita N, Yoshioka M, Ogawa N.
Brain Res 2001 Jan 19;889(1-2):225-8

Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist.
Tanaka K, Miyazaki I, Fujita N, Haque ME, Asanuma M, Ogawa N.
Neurochem Res 2001 Jan;26(1):31-6

Influence of interleukin-1beta gene polymorphisms on age-at-onset of sporadic Parkinson's disease.
Nishimura M, Mizuta I, Mizuta E, Yamasaki S, Ohta M, Kuno S.
Neurosci Lett 2000 Apr 21;284(1-2):73-6

Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score.
Araki I, Kuno S.
J Neurol Neurosurg Psychiatry 2000 Apr;68(4):429-33

Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes.
Ohta M, Mizuta I, Ohta K, Nishimura M, Mizuta E, Hayashi K, Kuno S.
Biochem Biophys Res Commun 2000 May 27;272(1):18-22

Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain.
Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T.
J Neural Transm 2000;107(3):335-41

A mutation in the microtubule-associated protein tau in pallido-

nigro-luysian degeneration.
Wszolek ZK, Uitti RJ, Hutton M.
Neurology 2000 May 23;54(10):2028-30

Meta-analysis of polymorphism of the catechol-O-methyltransferase gene in relation to the etiology of Parkinson's disease in Japan.
Mizuta I, Mizuta E, Yamasaki S, Kuno S, Yasuda M, Tanaka C.
Mov Disord 2000 Sep;15(5):1013-4

Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms.
Araki I, Kitahara M, Oida T, Kuno S.
J Urol 2000 Nov;164(5):1640-3

Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes.
Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Hayashi K, Kuno S.
Biochem Biophys Res Commun 2000 Dec 29;279(3):751-5

老年期パーキンソン病へのアプローチ 最近の進歩 新しい治療薬と今後の展開
久野貞子
Gerontology New Horizon 12 巻 1 号 Page58-64(1999.12)

標準治療と最新治療 メリット・デメリット Parkinson 病
久野貞子
Clinical Neuroscience 18 巻 3 号 Page348-349(2000.03)

【成人病の自己管理はどこまで有効か? その pit fall と対策,指導法】 パーキンソン病の自己管理
久野貞子

臨床成人病　30巻8号 Page976-980(2000.08)

Parkinson 病治療の進歩】 Parkinson 病の治療(3):症候別治療戦略 ジスキネジア　神経内科的治療
久野貞子
日本臨床　58巻10号 Page2110-2114(2000.10)

【Common disease の Evidence-based Medicine と Experience-based Medicine】 パーキンソン病の薬物療法
久野貞子
臨床成人病　30巻10号 Page1288-1292(2000.10)

【パーキンソン病治療の新しい考え方－第2世代ドパミンアゴニストを中心に－】 ドパミンアゴニストの使い方とカベルゴリンの特徴
久野貞子
Nikkei Medical　Page56-57 (2000.11)

【パーキンソン病を考える 29】
パーキンソン病と悪性症候群
久野貞子
SCOPE　39巻9号 Page18-19(2000)

【EBM(Evidence-Based Medicine)とパーキンソン病治療 ドパミンアゴニストを中心に】 パーキンソン病治療への応用　利点と問題点
久野貞子
新薬と臨床　49巻11号 Page1154-1161(2000.11)

パーキンソン病の薬物療法と悪性症候群の関係は？
久野貞子
Page 111-113
パーキンソン病 Q&A　平井俊策編　大阪：医薬ジャーナル社；2000

パーキンソン病の一般的予後は？
久野貞子

Page 134-135
パーキンソン病 Q&A 平井俊策編 大阪: 医薬ジャーナル社; 2000

パーキンソン病の内科的治療
久野貞子
Page 241-245
今日の治療指針 多賀須幸男,尾形悦朗 編 東京: 医学書院; 2000

病期別にみた薬物治療の実際
久野貞子
Page 139-146
パーキンソン病 ー診断と治療 柳原信夫編 東京: 金原出版; 2000